Altria or Bristol Myers Squibb: The One Dividend Stock I’d Hold for the Next 20 Years

Michael Douglass • 6 minute read
Reviewed by: Michael Douglass
Last updated Nov 18, 2026

89Stocker, towfiqu barbhuiya via Canva

Key Takeaways

  • Altria yields 5.7% and Bristol Myers Squibb yields 4.1%, and both raised part of their 2026 outlooks on Oct. 29.
  • Over the twelve months to Sept. 30, 2026, Bristol Myers paid out 55% of its free cash flow as dividends, against 78% at Altria.
  • Altria has raised its dividend 61 times in 57 years, while Bristol Myers’ dividend grew 2.9% in fiscal 2025, against 6.2% a year from fiscal 2020 to fiscal 2025.
  • Bristol Myers expects a $1.5 billion to $2 billion step down in Eliquis revenue in 2027, and Altria’s dividend growth goal runs through 2028.

Altria Group (MO) raised its 2026 earnings outlook on Oct. 29, two months after lifting its quarterly dividend 4.7% to $1.11 a share.

The same day, Bristol Myers Squibb (BMY) raised its 2026 revenue guidance to $49.75 billion to $50.25 billion. Its newer drugs are growing fast enough to cover older ones that are losing sales to generics.

If you could only hold one of them for the next 20 years, which should it be?

MetricAltria (MO)Bristol Myers Squibb (BMY)
Dividend yield5.7%4.1%
Annual dividend$4.44$2.52
Dividend growth, fiscal 2020-20254.1% a year6.2% a year
Dividend growth, fiscal 2015-20256.3% a year5.3% a year
Cash dividend payout ratio (TTM to Sept. 30, 2026)78%55%
Net debt/EBITDA (LTM)1.66x1.71x
Interest coverage (LTM)10.94x9.87x

Source: TIKR; annual dividend rates from StockAnalysis.

6 safe dividend stocks paying retirees 6%+ yields

There are over 100 stocks paying 6%+ annual dividends today.

But after an extensive investment review leveraging TIKR’s proprietary data, we now believe only six of them are truly safe for retirees.

They’re all yours as part of our new investment report. Learn more about how to get access right here.

Altria squeezes more out of fewer cigarettes

Altria ships fewer cigarettes every year, but it keeps earning more from them. Adjusted EPS rose 4.8% to $1.52 in the third quarter from a year before. Management now expects $5.66 to $5.74 for 2026, or 4.5% to 6.0% growth on 2025’s $5.42.

Over the twelve months to Sept. 30, 2026, Altria paid $7.12 billion in dividends out of $9.07 billion of free cash flow, a tight 78% cash dividend payout ratio. It has run that tight for years, as free cash flow rose from $8.15 billion in fiscal 2020 to $9.07 billion in fiscal 2025 and dividends paid rose from $6.29 billion to $6.96 billion:

Bar chart from TIKR of Altria Group's free cash flow vs. common dividends paid, $ billions, fiscal 2016–2025.
Altria Group (MO): free cash flow vs. common dividends paid, $ billions, fiscal 2016–2025 (TIKR)

Altria says in its third-quarter release that “We maintain our progressive dividend goal that targets mid-single digits dividend per share growth annually through 2028.” The risks are economic pressure on smokers and an FDA that has been slow to authorize the smoke-free products Altria is counting on.

Bristol Myers has more room, and a patent problem

Bristol Myers’ dividend has far more cash behind it than Altria’s. Over the twelve months to Sept. 30, 2026, it paid $5.12 billion in dividends out of $9.29 billion of free cash flow, a comfortable 55% cash dividend payout ratio. Free cash flow stayed between $12.0 billion and $15.2 billion in every fiscal year from 2020 to 2025, while dividends paid rose from $4.08 billion to $5.05 billion:

Bar chart from TIKR of Bristol-Myers Squibb Company's free cash flow vs. common dividends paid, $ billions, fiscal 2016–2025.
Bristol-Myers Squibb Company (BMY): free cash flow vs. common dividends paid, $ billions, fiscal 2016–2025 (TIKR)

The Growth Portfolio, led by Opdivo Qvantig, Breyanzi and Camzyos, rose 12% to $7.7 billion in the third quarter from a year before, lifting total revenue 7% to $13.1 billion. But generics cut Revlimid’s sales 47%, non-GAAP EPS fell 17% to $1.35, and the company expects Eliquis revenue to drop by $1.5 billion to $2 billion in 2027.

Dividend growth has slowed too: 2.9% in fiscal 2025, against 6.2% a year from fiscal 2020 to fiscal 2025. CFO David Elkins said on the third-quarter call that “business development remains a priority,” alongside “continuing to return cash to our shareholders through our commitment to the dividend.”

So which dividend wins?

If I could hold only one for the next 20 years, it’d be Altria. It has raised its dividend 61 times in 57 years. Its earnings are still climbing, from $4.95 of normalized EPS in fiscal 2023 to $5.42 in fiscal 2025, and analysts expect $6.16 by fiscal 2028:

Bar chart from TIKR of Altria Group's normalized EPS, actual and consensus estimates, $ per share, fiscal 2023-2028.
Altria Group (MO): normalized EPS, actual and consensus estimates, $ per share, fiscal 2023-2028 (TIKR)

$10,000 in Altria pays $570 a year today. At its 4.1% five-year growth rate, that becomes about $1,227 in year 20, a 12.3% yield on your original cash. Over the 20 years it adds up to about $17,182, which is about $1,709 more than Bristol Myers pays at its own 6.2% rate. At those rates, Bristol Myers’ check would only pass Altria’s in about 16 years (2043). At the pace each company raised in fiscal 2025, it never does, and Altria’s lead over the 20 years grows to about $6,076.

That doesn’t mean Bristol Myers’ dividend is in danger. It keeps nearly half its free cash flow after paying the dividend, and its newer drugs just pushed its revenue outlook higher. But its dividend growth has slowed while it hunts for deals and works to replace Eliquis. Over 20 years, I’d rather count on Altria’s bigger check and its long record of raising it.

Of course, Altria’s mid-single-digit goal only runs through 2028. With 78% of its free cash flow already going out, the streak depends on earnings that keep growing after that.

Forget Altria: 6 safe 6%+ dividend yields you can buy right now

Dividends can hold the key to enormous wealth. But only if you buy the right ones.

Picking the right high-yield dividend stock can be the difference between a dream retirement…and scraping by every month, waiting for the next Social Security check to clear.

We’ve identified six stocks yielding 6%+ that we believe every retiree should know about right now. (And Altria isn’t one of them.)

Learn more here.

Disclaimer:

Please note that the articles on TIKR are not intended to serve as investment or financial advice from TIKR or our content team, nor are they recommendations to buy or sell any stocks. We create our content based on TIKR Terminal’s investment data and analysts’ estimates. Our analysis might not include recent company news or important updates. TIKR has no position in any of the stocks mentioned. Thank you for reading, and happy investing!

Join thousands of investors worldwide who use TIKR to supercharge their investment analysis.

Sign Up for FREENo credit card required